Adriacell leverages its scientific expertise to develop a new class of anti-tumor therapeutics and powerful diagnostics for early cancer detection. The company is also working on delivery solutions for anti-infective drugs. With a patented system for studying DNA double strand breaks, Adriacell aims to make significant contributions to cancer research and diagnostics. Currently, Adriacell is evaluating a new class of therapeutics for cancer, with its main compound entering the pharmacokinetic and toxicology phases.